Anti-CD3 monoclonal antibody
Teplizumab
Brand names: Tzield
Adult dose
Dose: 14-day daily IV infusion course (weight-based) — specialist
Route: IV
Frequency: daily x14
Clinical pearls
- Delays onset of stage 3 type 1 diabetes in adults/adolescents (≥8y) with stage 2 T1D
- Specialist endocrine; pre-medication
Contraindications
- Active serious infection
- Pregnancy
- Hypersensitivity
Side effects
- CRS
- Cytopenias (especially lymphopenia)
- Severe infections
- Severe rash
- Hypersensitivity
Interactions
- Live vaccines
- Immunosuppressives
Monitoring
- FBC
- LFTs
- CRS
- Vaccinations
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/teplizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016